CA2939529C - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate - Google Patents
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate Download PDFInfo
- Publication number
- CA2939529C CA2939529C CA2939529A CA2939529A CA2939529C CA 2939529 C CA2939529 C CA 2939529C CA 2939529 A CA2939529 A CA 2939529A CA 2939529 A CA2939529 A CA 2939529A CA 2939529 C CA2939529 C CA 2939529C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- thiazol
- phenyl
- pyridinyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QPIDAZSAUYNBAC-UHFFFAOYSA-N methanesulfonic acid;n-methyl-n-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide;hydrate Chemical compound O.CS(O)(=O)=O.N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 QPIDAZSAUYNBAC-UHFFFAOYSA-N 0.000 title claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 23
- 150000001642 boronic acid derivatives Chemical class 0.000 claims abstract description 13
- HBXRPXYBMZDIQL-UHFFFAOYSA-N 1$l^{2}-borolane Chemical compound [B]1CCCC1 HBXRPXYBMZDIQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- -1 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-methyl-2-[4-(2-pyridinyl)phenyl]acetamide Chemical compound 0.000 claims description 22
- KPAUORDXNFURBA-UHFFFAOYSA-N 2-(4-pyridin-2-ylphenyl)acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=N1 KPAUORDXNFURBA-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 12
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- BIOOXWXQBSHAMB-UHFFFAOYSA-N borinane Chemical compound B1CCCCC1 BIOOXWXQBSHAMB-UHFFFAOYSA-N 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229940126062 Compound A Drugs 0.000 claims description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 5
- 239000012445 acidic reagent Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- LVLDBZCFWNSVLJ-UHFFFAOYSA-N 4-methyl-2-(methylamino)-1,3-thiazole-5-sulfonamide Chemical compound CNC1=NC(C)=C(S(N)(=O)=O)S1 LVLDBZCFWNSVLJ-UHFFFAOYSA-N 0.000 claims 1
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 abstract description 72
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract description 35
- 238000003786 synthesis reaction Methods 0.000 abstract description 20
- 230000007774 longterm Effects 0.000 abstract description 8
- 150000003606 tin compounds Chemical class 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 3
- 239000012458 free base Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 239000013078 crystal Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 229960004150 aciclovir Drugs 0.000 description 9
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 7
- 235000010980 cellulose Nutrition 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229960001179 penciclovir Drugs 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 229960004396 famciclovir Drugs 0.000 description 5
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229940093257 valacyclovir Drugs 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 235000012216 bentonite Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960000724 cidofovir Drugs 0.000 description 4
- 239000012050 conventional carrier Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 229960005102 foscarnet Drugs 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960004716 idoxuridine Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 229960003962 trifluridine Drugs 0.000 description 4
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000004849 borolanes Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 150000004877 borinanes Chemical class 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- KVCUKLPSRGQDTN-UHFFFAOYSA-N ethyl 2-(4-pyridin-2-ylphenyl)acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C1=CC=CC=N1 KVCUKLPSRGQDTN-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- HDWHGDDNMJOCCU-UHFFFAOYSA-N trimethyl(pyridin-2-yl)stannane Chemical compound C[Sn](C)(C)C1=CC=CC=N1 HDWHGDDNMJOCCU-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NVLPXWAHYJWLPN-UHFFFAOYSA-N 1$l^{2},2$l^{2}-diborolane Chemical compound [B]1[B]CCC1 NVLPXWAHYJWLPN-UHFFFAOYSA-N 0.000 description 1
- WUYQAYADHXKJTF-UHFFFAOYSA-N 1,3,2-dioxaborinane Chemical compound B1OCCCO1 WUYQAYADHXKJTF-UHFFFAOYSA-N 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- MDNDJMCSXOXBFZ-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane Chemical compound O1CC(C)(C)COB1B1OCC(C)(C)CO1 MDNDJMCSXOXBFZ-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- KWAHADSKPFGJQF-UHFFFAOYSA-N 2-iodoprop-1-ene Chemical compound CC(I)=C KWAHADSKPFGJQF-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FJZXXMUCXAWHQY-UHFFFAOYSA-N 4,4,6,6-tetramethyl-1,3,2-dioxaborinane Chemical compound CC1(C)CC(C)(C)OBO1 FJZXXMUCXAWHQY-UHFFFAOYSA-N 0.000 description 1
- ARSUQHZDPBOKDP-UHFFFAOYSA-N 4,4,6-trimethyl-1,3,2-dioxaborinane Chemical compound CC1CC(C)(C)OBO1 ARSUQHZDPBOKDP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- PWATUXGJXJPDET-UHFFFAOYSA-N 5,5-dimethyl-1,3,2-dioxaborinane Chemical compound CC1(C)COBOC1 PWATUXGJXJPDET-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- OLDXRTOEUPVZKB-UHFFFAOYSA-N B1CCCC1 Chemical compound B1CCCC1 OLDXRTOEUPVZKB-UHFFFAOYSA-N 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- MLSXGCQLXXPFPB-UHFFFAOYSA-N C1CCCC2OBOC21 Chemical compound C1CCCC2OBOC21 MLSXGCQLXXPFPB-UHFFFAOYSA-N 0.000 description 1
- RUGBSZGVVVVCEF-UHFFFAOYSA-N CC1(C)OBOC(C)(C)C1(C)C Chemical compound CC1(C)OBOC(C)(C)C1(C)C RUGBSZGVVVVCEF-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229910021120 PdC12 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- DIOLOCSXUMYFJN-UHFFFAOYSA-N calcium;azane Chemical compound N.[Ca+2] DIOLOCSXUMYFJN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011083 clear filtration Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- JWFOBEGWSKKPRL-UHFFFAOYSA-N di(propan-2-yloxy)boron Chemical compound CC(C)O[B]OC(C)C JWFOBEGWSKKPRL-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZFDCWHPNBWPPHG-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(Br)C=C1 ZFDCWHPNBWPPHG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000005473 herpetic whitlow Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000010935 polish filtration Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an improved and shortened synthesis of N -[5-aminosulfonyI)-4-methyl-1 ,3-thiazol-2-yl]-N-methyl-2-[4-(2- pyridinyl)phenyl] acetamide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl] -N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions. Also the present invention relates to the crystalline mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-N-methyl-2-[4-(2- pyridinyl)phenyl] acetamide in a definite particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4- (2-pyridinyl) phenyl]acetamide mesylate monohydrate having the afore-mentioned particle size distribution and specific surface area range.
Description
N45-(Aminosulfony1)-4-methyl-1,3-thiazol-2-y1FN-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate Specification The present invention relates to an improved synthesis of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions.
Background of the invention Synthesis of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide is known from EP 1244641 B1 , and the use of acidic components including methanesulfonic acid for the formulation of tablets containing micronized N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-2-[4-(2-pyridinyl) phenyl]acetamide is disclosed by WO 2006/103011 Al.
It is the objective of the present invention to provide an improved synthesis for the compound N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl) phenyl]acetamide and a stable salt which exhibits increased long term stability and improved release kinetics from pharmaceutical formulations as well as a pharmaceutical formulations comprising that salt with improved release kinetics.
Description of the invention The present invention relates to an improved and novel synthesis of the pharmaceutically active compound N-[5-(aminosulfonyI)-4-methyl-1 ,3-thiazol-2-y11-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide as well as its mesylate salt.
This improved synthesis starts from the same compounds as the older known synthesis of the state of the art but combines three reaction steps by the use of a boronic acid derivatives or borolane reagent. This modification makes the complete synthesis easier by avoiding two separation and purification steps and is also able to increase the yield.
The older known synthesis as described in EP 1244641 B1 on page 21 starts from
Background of the invention Synthesis of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide is known from EP 1244641 B1 , and the use of acidic components including methanesulfonic acid for the formulation of tablets containing micronized N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-2-[4-(2-pyridinyl) phenyl]acetamide is disclosed by WO 2006/103011 Al.
It is the objective of the present invention to provide an improved synthesis for the compound N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl) phenyl]acetamide and a stable salt which exhibits increased long term stability and improved release kinetics from pharmaceutical formulations as well as a pharmaceutical formulations comprising that salt with improved release kinetics.
Description of the invention The present invention relates to an improved and novel synthesis of the pharmaceutically active compound N-[5-(aminosulfonyI)-4-methyl-1 ,3-thiazol-2-y11-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide as well as its mesylate salt.
This improved synthesis starts from the same compounds as the older known synthesis of the state of the art but combines three reaction steps by the use of a boronic acid derivatives or borolane reagent. This modification makes the complete synthesis easier by avoiding two separation and purification steps and is also able to increase the yield.
The older known synthesis as described in EP 1244641 B1 on page 21 starts from
2-bromopyridine. In step 1 the 2-trimethylstannanylpyridine is prepared in a 45 to 50%
yield (of the theory). The 2-trimethylstannanylpyridine is subsequently reacted with ethyl (4-bromophenyl)acetate in order to obtain the ethyl (4-pyridin-2-ylphenyl)acetate in a 75% yield. In the third step the ethyl (4-pyridin-2-ylphenyl)acetate is saponified to the (4-pyridin-2-ylphenyl)acetic acid with about 95% yield of theory.
Consequently, the state of the art synthesis as shown below Br Step 1 Sn(C H3)3 Step 2, 75%
m 1 45-50% '=.%N Step 3, NaOH I Et0H, 95% \ N
comprises 3 steps with an over all yield of about 34% including two separation and purification steps which take time and involve the use of solvents for extracting and washing the desired compounds as well as arrangements for purifying them.
The synthesis of the present invention as shown below H
/
0¨B
CO0C2H5 Pd(OAc)2, PPh3, Et3N
0 +
Br O¨B
toluene, reflux 1 Step NaOH ci 40%
N
A
COOH
N
combines the three discrete steps by using boronic acid derivatives or borolane or a borinane reagent which allows for synthesis of the key intermediate (4-pyridin-ylphenyl)acetic acid in a single stage with an over all yield of about 40% of theory avoiding the two separation and purification steps of the state of the art synthesis.
yield (of the theory). The 2-trimethylstannanylpyridine is subsequently reacted with ethyl (4-bromophenyl)acetate in order to obtain the ethyl (4-pyridin-2-ylphenyl)acetate in a 75% yield. In the third step the ethyl (4-pyridin-2-ylphenyl)acetate is saponified to the (4-pyridin-2-ylphenyl)acetic acid with about 95% yield of theory.
Consequently, the state of the art synthesis as shown below Br Step 1 Sn(C H3)3 Step 2, 75%
m 1 45-50% '=.%N Step 3, NaOH I Et0H, 95% \ N
comprises 3 steps with an over all yield of about 34% including two separation and purification steps which take time and involve the use of solvents for extracting and washing the desired compounds as well as arrangements for purifying them.
The synthesis of the present invention as shown below H
/
0¨B
CO0C2H5 Pd(OAc)2, PPh3, Et3N
0 +
Br O¨B
toluene, reflux 1 Step NaOH ci 40%
N
A
COOH
N
combines the three discrete steps by using boronic acid derivatives or borolane or a borinane reagent which allows for synthesis of the key intermediate (4-pyridin-ylphenyl)acetic acid in a single stage with an over all yield of about 40% of theory avoiding the two separation and purification steps of the state of the art synthesis.
3 As an added benefit, the use of boron containing reagents is advantageous over the use of the toxic organic tin compounds in that the resulting boric acid by-product can be easily removed by an aqueous wash. In contrast, organic tin compounds are not only a known problem in process waste streams, but are also noted for notoriously contaminating the resulting products of the down-stream synthesis. The (4-pyridin-2-ylphenyl)acetic acid is reacted with 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide to the final product which is then converted to the definite mesylate monohydrate salt as shown below.
H¨N N I
THE
=
o NMP
¨S
¨
N N 0'11 NH2 Et0H
N N
--S
N, 0-7/ ¨NH2 H3c so3 or H20 Thus the present invention is directed to a method for synthesizing N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methy1-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate salt thereof according to the following steps:
Step A: Reacting compound A of the following general formula A*
A*
*
wherein Fe represents a leaving group and
H¨N N I
THE
=
o NMP
¨S
¨
N N 0'11 NH2 Et0H
N N
--S
N, 0-7/ ¨NH2 H3c so3 or H20 Thus the present invention is directed to a method for synthesizing N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methy1-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate salt thereof according to the following steps:
Step A: Reacting compound A of the following general formula A*
A*
*
wherein Fe represents a leaving group and
4 R2 represents an alkyl residue with 1 to 6 carbon atoms or a cycloalkyl residue with 3 to 6 carbon atoms, with a boronic acid derivative, borolane, borinane or diboronic acid reagent under elimination of R1¨H or R1-B(OR)2 and formation of an intermediate boronic acid derivative of compound A, wherein preferred catalysts for the reaction are the reagent systems palladium acetate with triethylamine and triphenylphosphine or PdC12(PPh3)2 with triethylamine, wherein the intermediate boronic acid derivative is then reacted with the pyridine compound B of the following general formula B*
B*
wherein R3 represents a leaving group under basic conditions in order to obtain the (4-pyridin-2-ylphenyl)acetic acid as an alkaline solution of the corresponding carboxylate salt.
The resulting (4-pyridin-2-ylphenyl)acetic acid was purified by simple washings at different pH and clear filtration steps followed by precipitation or crystallization, preferably by properly adjusting the pH of an aqueous acidic solution of (4-pyridin-2-ylphenyl)acetic acid with an appropriate amount of base to 3.5 ¨ 5.0, preferably 3.8 ¨
4.7. Beside the simple washing and filtration step, no further purification of the (4-pyridin-2-ylphenyl)acetic acid or any of the intermediates by, for instance, recrystallization or chromatography is required.
Step B: Reacting (4-pyridin-2-ylphenyl)acetic acid obtained from step A with 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide H¨N
0' NH2 in order to obtain N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methy1-244-(2-pyridinyl)phenyl]acetamide of the formula 11101 0 r2.1/ ______________________________________ CH3 N 0 if 'NH2 The N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]
B*
wherein R3 represents a leaving group under basic conditions in order to obtain the (4-pyridin-2-ylphenyl)acetic acid as an alkaline solution of the corresponding carboxylate salt.
The resulting (4-pyridin-2-ylphenyl)acetic acid was purified by simple washings at different pH and clear filtration steps followed by precipitation or crystallization, preferably by properly adjusting the pH of an aqueous acidic solution of (4-pyridin-2-ylphenyl)acetic acid with an appropriate amount of base to 3.5 ¨ 5.0, preferably 3.8 ¨
4.7. Beside the simple washing and filtration step, no further purification of the (4-pyridin-2-ylphenyl)acetic acid or any of the intermediates by, for instance, recrystallization or chromatography is required.
Step B: Reacting (4-pyridin-2-ylphenyl)acetic acid obtained from step A with 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide H¨N
0' NH2 in order to obtain N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methy1-244-(2-pyridinyl)phenyl]acetamide of the formula 11101 0 r2.1/ ______________________________________ CH3 N 0 if 'NH2 The N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]
5 acetamide is thereafter most preferably converted (as step C) to the so far unknown monohydrate of the mesylate salt of N15-(aminosulfony1)-4-methyl-1,3-thiazol-2-methyl-244-(2-pyridinyl)phenyl]acetamide. It has to be stated that a mesylate salt is disclosed in WO 2006/103011 Al but not the specific mono mesylate monohydrate salt which exhibits the improved properties.
The inventive method for synthesizing the N15-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate may further comprise step D directed to the preparation of a pharmaceutical composition of said methanesulfonic acid monohydrate salt:
Step D: Preparing a pharmaceutical composition of the crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyli-acetamide methanesulfonic acid monohydrate with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
Such a pharmaceutical composition can be prepared by admixing or blending the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl) phenyl]-acetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
The inventive method may further comprise step E following the step D:
Step E: Adding acetylsalicylic acid, trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir, penciclovir, valaciclovir and/or famciclovir to the pharmaceutical composition of the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate and at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
The inventive method for synthesizing the N15-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate may further comprise step D directed to the preparation of a pharmaceutical composition of said methanesulfonic acid monohydrate salt:
Step D: Preparing a pharmaceutical composition of the crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyli-acetamide methanesulfonic acid monohydrate with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
Such a pharmaceutical composition can be prepared by admixing or blending the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl) phenyl]-acetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
The inventive method may further comprise step E following the step D:
Step E: Adding acetylsalicylic acid, trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir, penciclovir, valaciclovir and/or famciclovir to the pharmaceutical composition of the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate and at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
6 Thus after step E a pharmaceutical composition containing acetylsalicylic acid, trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir, penciclovir, valaciclovir or famciclovir or a pharmaceutical composition containing acetylsalicylic acid and trifluridine or acetylsalicylic acid and idoxuridine or acetylsalicylic acid and foscarnet or acetylsalicylic acid and cidofovir or acetylsalicylic acid and ganciclovir or acetylsalicylic acid and aciclovir or acetylsalicylic acid and penciclovir or acetylsalicylic acid and valaciclovir or acetylsalicylic acid and famciclovir in combination with crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent is obtained. Consequently the present invention relates also to a pharmaceutical composition containing acetylsalicylic acid or aciclovir or penciclovir or acetylsalicylic acid and aciclovir or acetylsalicylic acid and penciclovir and crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenylFacetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent. Some suppliers use the name acyclovir instead of aciclovir.
The term "leaving group" as used herein is a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage.
Leaving groups can be anions or neutral molecules. Common anionic leaving groups are halides such as Cr, Br-, and r, and sulfonate esters, such as para-toluenesulfonate (''tosylate", Ts0-), trifluoromethanesulfonate ("triflate", Tf0-, CF3S020-), benzenesulfonate ("besylate, C6H5S020-) or methanesulfonate ("mesylate'', Ms0-).
General formula A* as shown below A*
covers all phenyl acetic acid esters having a leaving group on the phenyl residue in position 4.
Thus R1 preferably represents ¨F, ¨Cl, ¨Br, ¨I, ¨OMs, ¨0Tf and ¨0Ts. The group "¨OMs" refers to ¨0Mesylate, the group "¨OTf' refers to ¨0Triflate and the group "¨OTs"
refers to ¨0Tosylate.
The group R2 represents an alkyl residue with 1 to 6 carbon atoms or a cycloalkyl residue with 3 to 6 carbon atoms, and preferably ¨CH3, ¨C2H5, ¨C31-17,
The term "leaving group" as used herein is a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage.
Leaving groups can be anions or neutral molecules. Common anionic leaving groups are halides such as Cr, Br-, and r, and sulfonate esters, such as para-toluenesulfonate (''tosylate", Ts0-), trifluoromethanesulfonate ("triflate", Tf0-, CF3S020-), benzenesulfonate ("besylate, C6H5S020-) or methanesulfonate ("mesylate'', Ms0-).
General formula A* as shown below A*
covers all phenyl acetic acid esters having a leaving group on the phenyl residue in position 4.
Thus R1 preferably represents ¨F, ¨Cl, ¨Br, ¨I, ¨OMs, ¨0Tf and ¨0Ts. The group "¨OMs" refers to ¨0Mesylate, the group "¨OTf' refers to ¨0Triflate and the group "¨OTs"
refers to ¨0Tosylate.
The group R2 represents an alkyl residue with 1 to 6 carbon atoms or a cycloalkyl residue with 3 to 6 carbon atoms, and preferably ¨CH3, ¨C2H5, ¨C31-17,
7 -CH(CH3)2, -C4H5, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, C5H11, -C6H13, cyclo-C3H5, cyclo-C4H7, cyclo-05H9, cyclo-C6Fl11. More preferred are -CH3, -C2H5, -C3H7, -CH(CH3)2, -C41-19, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, and -05H11. Especially preferred are -CH3, -C2H5, -C3H7, and -CH(CH3)2.
Various borolanes and borinanes as well as the corresponding diboronic acid derivatives can be used in step A of the inventive synthesis disclosed herein.
Preferred are borolanes of the following general formula:
R10- -OR"
wherein R' and R" are independently of each other any substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms, or R' and R'' can also form together with the boron atom a heterocyclic ring wherein R' and R" together form a substituted or unsubstituted, linear or branched alkylen group with 2 to 10 carbon atoms. Preferably R' and R" represent independently of each other -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, and -051-111. The cyclic borolanes are preferred.
The following borolanes, borinanes and diboronic acid derivatives are preferred:
0 0 1001 /B¨H 0 Ra Rf Ra (Rd 0 Rb Re RI3 Re Rc Rd Borolane Catecholboran Borinane Rd Ra e f Ra RctO\B¨B0p-'7 0 /< d Rb RE
/IC l:Rc Rb b B¨B
RR
Ra Rd Ra Rf Diborolane Diborinane
Various borolanes and borinanes as well as the corresponding diboronic acid derivatives can be used in step A of the inventive synthesis disclosed herein.
Preferred are borolanes of the following general formula:
R10- -OR"
wherein R' and R" are independently of each other any substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms, or R' and R'' can also form together with the boron atom a heterocyclic ring wherein R' and R" together form a substituted or unsubstituted, linear or branched alkylen group with 2 to 10 carbon atoms. Preferably R' and R" represent independently of each other -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, and -051-111. The cyclic borolanes are preferred.
The following borolanes, borinanes and diboronic acid derivatives are preferred:
0 0 1001 /B¨H 0 Ra Rf Ra (Rd 0 Rb Re RI3 Re Rc Rd Borolane Catecholboran Borinane Rd Ra e f Ra RctO\B¨B0p-'7 0 /< d Rb RE
/IC l:Rc Rb b B¨B
RR
Ra Rd Ra Rf Diborolane Diborinane
8 wherein Re, Rb, Rb, Rd, Re and Rf represent independently of each other a substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms. Preferred are the linear alkyl residues with 1 to 6 carbon atoms, and most preferred are ¨CH3, ¨C2H5, ¨C3H7 and ¨CH(CH3)2.
Especially preferred examples for the above borone containing compounds are 4,4,5,5-tetramethyl[1,3,2]dioxaborolane (pinacolborane), [1,3,2]dioxaborolane, [1,3,2]dioxaborinane, 5,5-dimethyl[1,3,2]dioxaborinane, 4,6,6-trimethyl[1,3,2]-dioxaborinane, 4,4,6,6-tetramethyl[1,3,2]-dioxaborinane, 4,4,5,5,6,6-hexamethyl[1,3,2]-dioxaborinane, diisopropoxyborane, hexahydrobenzo[1,3,2]di-oxaborole, 9,9-dimethy1-3,5-dioxa-4-bora-tricyclo-[6.1.1.62'e]decane, 6,9,9-trimethy1-3,5-dioxa-4-bora-tricyclo[6.1.1.62'6]decane, B2Pin2 (bis(pinacolato)diborane), bis(neopentylglycolato)diboron and catecholboran.
In step A this boronic acid derivative, borolane, borinane or diboronic acid reagent is reacted with a compound A of general formula A* in order to obtain an intermediate borolan or borinane reagent which is not isolated and purified. This reaction may be supported by the use of either catalysts prepared in situ by combination of palladium salts such as [Pd(OAc)2] and PdC12 with triphenylphosphine (PPh3), tri-ortho-tolylphosphine (P(o-To1)3), tricyclohexylphosphine (PCy3), tri-tert.-butylphosphine, 1,4-Bis-(diphenylphosphino)-butane (dppb), and 1,1'-Bis-(diphenylphosphino)-ferrocene dppf or preformed catalysts such as Pd(PPh3)2C12, Pd(PPh3)4, Fibrecat 1032, and Pd(dppf)Cl2 in the presence of a variety of organic and inorganic bases such as triethylamine (Et3N), Na0Ac, KOAc, and K3PO4. For this reaction heating to temperature between 70 C and 150 C, preferably between 80 C and 130 C, more preferably between 90 C and 110 C is preferred.
Moreover aprotic and preferably apolar solvents and preferably aromatic solvents such as benzene or toluene or xylenes are used.
This step A improves the state of the art synthesis by avoiding the use of toxic organic tin compounds which are a big problem in the purification of the waste streams as well as the actual product(s) of the reaction which are finally drugs for use in humans.
The intermediate boronic acid reagent is subsequently reacted with a pyridinyl compound of the general formula B*, wherein R3 represents a leaving group. Thus R3 represents ¨F, ¨Cl, ¨Br, ¨1, ¨OMs, ¨0Tf and ¨0Ts and preferably ¨Cl or -Br.
Especially preferred examples for the above borone containing compounds are 4,4,5,5-tetramethyl[1,3,2]dioxaborolane (pinacolborane), [1,3,2]dioxaborolane, [1,3,2]dioxaborinane, 5,5-dimethyl[1,3,2]dioxaborinane, 4,6,6-trimethyl[1,3,2]-dioxaborinane, 4,4,6,6-tetramethyl[1,3,2]-dioxaborinane, 4,4,5,5,6,6-hexamethyl[1,3,2]-dioxaborinane, diisopropoxyborane, hexahydrobenzo[1,3,2]di-oxaborole, 9,9-dimethy1-3,5-dioxa-4-bora-tricyclo-[6.1.1.62'e]decane, 6,9,9-trimethy1-3,5-dioxa-4-bora-tricyclo[6.1.1.62'6]decane, B2Pin2 (bis(pinacolato)diborane), bis(neopentylglycolato)diboron and catecholboran.
In step A this boronic acid derivative, borolane, borinane or diboronic acid reagent is reacted with a compound A of general formula A* in order to obtain an intermediate borolan or borinane reagent which is not isolated and purified. This reaction may be supported by the use of either catalysts prepared in situ by combination of palladium salts such as [Pd(OAc)2] and PdC12 with triphenylphosphine (PPh3), tri-ortho-tolylphosphine (P(o-To1)3), tricyclohexylphosphine (PCy3), tri-tert.-butylphosphine, 1,4-Bis-(diphenylphosphino)-butane (dppb), and 1,1'-Bis-(diphenylphosphino)-ferrocene dppf or preformed catalysts such as Pd(PPh3)2C12, Pd(PPh3)4, Fibrecat 1032, and Pd(dppf)Cl2 in the presence of a variety of organic and inorganic bases such as triethylamine (Et3N), Na0Ac, KOAc, and K3PO4. For this reaction heating to temperature between 70 C and 150 C, preferably between 80 C and 130 C, more preferably between 90 C and 110 C is preferred.
Moreover aprotic and preferably apolar solvents and preferably aromatic solvents such as benzene or toluene or xylenes are used.
This step A improves the state of the art synthesis by avoiding the use of toxic organic tin compounds which are a big problem in the purification of the waste streams as well as the actual product(s) of the reaction which are finally drugs for use in humans.
The intermediate boronic acid reagent is subsequently reacted with a pyridinyl compound of the general formula B*, wherein R3 represents a leaving group. Thus R3 represents ¨F, ¨Cl, ¨Br, ¨1, ¨OMs, ¨0Tf and ¨0Ts and preferably ¨Cl or -Br.
9 The corresponding (4-pyridin-2-ylphenyl)acetic acid ester is in situ treated with an aqueous base in order to cleave the ester linkage. It could be advantageous to heat the reaction mixture during the coupling / saponification step to moderate temperature and preferably to temperature between 40 C and 90 C, more preferably between 45 C
and 80 C, still more preferably between 50 C and 70 C and most preferably between and 65 C.
After purification and isolation of the key intermediate (4-pyridin-2-ylphenyl)acetic acid, the (4-pyridin-2-ylphenyl)acetic acid was obtained in a yield of at least 40% of theory including only one isolation and purification step.
Further advantages of the present method are:
= Purification and Pd removal by successive washes of aqueous alkaline and acidic product solutions with organic solvents (toluene, MIBK, Et0Ac, MeTHF etc.).
= Additional Pd depletion by charcoal / Celitee treatment.
= Crystallization is possible from either alkaline or acidic aqueous solutions by neutralization (at preferably 50-70 C) Thereafter the (4-pyridin-2-ylphenyl)acetic acid was reacted with 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide of the formula /
H¨N
os which was prepared according to the synthesis disclosed in EP 1244641 B1 in order to obtain N{5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methy1-2-[4-(2-pyridinyl)phenyl]
acetamide of the formula --S
In WO 01/47904 A the amide coupling reaction is described using HOBT (1-Hydroxy-1H-benzotriazole hydrate) in DMF which ¨ due to its explosive character ¨
generally causes problems during up-scaling. In addition, during the optimization process the solvent 5 DMF had been detected as cause for a variety of by-products (from Vilsmaier type formylations).
Attempts for improved coupling conditions resulted surprisingly in the successful use of EDC x HCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) without HOBT
and 80 C, still more preferably between 50 C and 70 C and most preferably between and 65 C.
After purification and isolation of the key intermediate (4-pyridin-2-ylphenyl)acetic acid, the (4-pyridin-2-ylphenyl)acetic acid was obtained in a yield of at least 40% of theory including only one isolation and purification step.
Further advantages of the present method are:
= Purification and Pd removal by successive washes of aqueous alkaline and acidic product solutions with organic solvents (toluene, MIBK, Et0Ac, MeTHF etc.).
= Additional Pd depletion by charcoal / Celitee treatment.
= Crystallization is possible from either alkaline or acidic aqueous solutions by neutralization (at preferably 50-70 C) Thereafter the (4-pyridin-2-ylphenyl)acetic acid was reacted with 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide of the formula /
H¨N
os which was prepared according to the synthesis disclosed in EP 1244641 B1 in order to obtain N{5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methy1-2-[4-(2-pyridinyl)phenyl]
acetamide of the formula --S
In WO 01/47904 A the amide coupling reaction is described using HOBT (1-Hydroxy-1H-benzotriazole hydrate) in DMF which ¨ due to its explosive character ¨
generally causes problems during up-scaling. In addition, during the optimization process the solvent 5 DMF had been detected as cause for a variety of by-products (from Vilsmaier type formylations).
Attempts for improved coupling conditions resulted surprisingly in the successful use of EDC x HCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) without HOBT
10 in NMP/THF solvent combinations. Thus Step B of the above-mentioned method is preferably carried out with EDC x HCI as coupling agent (without HOBT) in THF
/ NMP
solvent mixtures having a ratio of 10: Ito 1:1. The following re-crystallization from THE
/ water resulted in a depletion of Pd to < 5 ppm. A total yield of > 80% for coupling and recrystallization could be achieved.
Thus the present invention also relates to the compound N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-2-[4-(2-pyridinyl)phenyl]acetamide obtained according to the synthesis as disclosed herein.
This N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]
acetamide was thereafter converted to the crystalline mesylate monohydrate salt which was not disclosed in the state of the art so far. A not stoichiometric mesylate salt was already known in the state of the art, but not the definite and stoichiometric mono mesylate monohydrate salt having exactly one mol equivalent water and one mol equivalent mesylate per mol equivalent N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyl]acetamide.
Thus the present invention relates to the compound N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyliacetamide methanesulfonic acid monohydrate and especially to crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate as well as to crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate obtainable and obtained according to the synthesis as disclosed herein. The N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacet-amide methanesulfonic acid monohydrate is substantially pure (purity above 96 weight-%, preferably > 98 weight-% and more preferably > 99 weight-%) and is the definite monohydrate, i.e. 1 mol N-[5-(aminosulfonyI)-4-methyl-
/ NMP
solvent mixtures having a ratio of 10: Ito 1:1. The following re-crystallization from THE
/ water resulted in a depletion of Pd to < 5 ppm. A total yield of > 80% for coupling and recrystallization could be achieved.
Thus the present invention also relates to the compound N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-2-[4-(2-pyridinyl)phenyl]acetamide obtained according to the synthesis as disclosed herein.
This N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]
acetamide was thereafter converted to the crystalline mesylate monohydrate salt which was not disclosed in the state of the art so far. A not stoichiometric mesylate salt was already known in the state of the art, but not the definite and stoichiometric mono mesylate monohydrate salt having exactly one mol equivalent water and one mol equivalent mesylate per mol equivalent N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyl]acetamide.
Thus the present invention relates to the compound N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyliacetamide methanesulfonic acid monohydrate and especially to crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate as well as to crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate obtainable and obtained according to the synthesis as disclosed herein. The N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacet-amide methanesulfonic acid monohydrate is substantially pure (purity above 96 weight-%, preferably > 98 weight-% and more preferably > 99 weight-%) and is the definite monohydrate, i.e. 1 mol N-[5-(aminosulfonyI)-4-methyl-
11 1 ,3-thiazol-2-y11-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate contains 1 mol water and 1 mol mesylate anion in a regular crystalline structure as shown in Figures 2 and 3.
The crystalline mesylate monohydrate salt of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide is formed from a supersaturated solution of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide and methanesulfonic acid by crystallization under controlled conditions.
Preferred conditions for the crystallization are the addition of methanesulfonic acid at elevated temperatures, and preferably between 30 C and 90 C, more preferably between 35 C and 80 C, still more preferably between 40 C and 70 C, still more preferably between 45 C and 60 C and most preferably at 50 C ¨ 55 C to the mixture of an organic solvent and water containing N[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]
acet-amide yielding a supersaturated solution of the mesylate of N-[5-(aminosulfonyI)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide.
Organic solvents which are miscible or consolute with water are preferred such as Me0H, Et0H, n-PrOH, I-PrOH, acetonitrile, THF, acetone. Moreover it is preferred to add seed crystals of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyllacetamide methanesulfonic acid monohydrate to this supersaturated mixture also at elevated temperatures like 30 C to 90 C, preferably 35 C to 80 C, more preferably 40 C
to 70 C, still more preferably 45 C to 60 C and most preferably at 50 C ¨ 55 C. Also moderate to slow stirring of this mixture and a slow cooling of this mixture to room temperature are preferred.
Furthermore it is preferred to add the methanesulfonic acid over 5 to 15 minutes at the elevated temperature and to keep the resulting mixture at this elevated temperature for 0.5 to 5 hour and more preferably 1 to 2 hours after completion of the addition of the methanesulfonic acid. The cooling to room temperature is performed within 1 to 5 hour and preferably 2 to 3 hours and the mixture is thereafter slowly stirred for preferably another hour at room temperature. Then the crystals are filtered off, washed with alcohol/water and preferably dried under vacuum at a temperature between 20 C and 60 C, preferably starting at 20 C and ending at 60 C.
The crystalline mesylate monohydrate salt of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyl]acetamide exhibits increased long term stability properties and a desired or improved release kinetic especially from pharmaceutical compositions and thus allows the preparation of long term stable pharmaceutical compositions. The long term stability of the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
The crystalline mesylate monohydrate salt of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide is formed from a supersaturated solution of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide and methanesulfonic acid by crystallization under controlled conditions.
Preferred conditions for the crystallization are the addition of methanesulfonic acid at elevated temperatures, and preferably between 30 C and 90 C, more preferably between 35 C and 80 C, still more preferably between 40 C and 70 C, still more preferably between 45 C and 60 C and most preferably at 50 C ¨ 55 C to the mixture of an organic solvent and water containing N[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]
acet-amide yielding a supersaturated solution of the mesylate of N-[5-(aminosulfonyI)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide.
Organic solvents which are miscible or consolute with water are preferred such as Me0H, Et0H, n-PrOH, I-PrOH, acetonitrile, THF, acetone. Moreover it is preferred to add seed crystals of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyllacetamide methanesulfonic acid monohydrate to this supersaturated mixture also at elevated temperatures like 30 C to 90 C, preferably 35 C to 80 C, more preferably 40 C
to 70 C, still more preferably 45 C to 60 C and most preferably at 50 C ¨ 55 C. Also moderate to slow stirring of this mixture and a slow cooling of this mixture to room temperature are preferred.
Furthermore it is preferred to add the methanesulfonic acid over 5 to 15 minutes at the elevated temperature and to keep the resulting mixture at this elevated temperature for 0.5 to 5 hour and more preferably 1 to 2 hours after completion of the addition of the methanesulfonic acid. The cooling to room temperature is performed within 1 to 5 hour and preferably 2 to 3 hours and the mixture is thereafter slowly stirred for preferably another hour at room temperature. Then the crystals are filtered off, washed with alcohol/water and preferably dried under vacuum at a temperature between 20 C and 60 C, preferably starting at 20 C and ending at 60 C.
The crystalline mesylate monohydrate salt of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyl]acetamide exhibits increased long term stability properties and a desired or improved release kinetic especially from pharmaceutical compositions and thus allows the preparation of long term stable pharmaceutical compositions. The long term stability of the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
12 is superior in comparison to the free base form of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinypphenyl].
Moreover the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyI)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide exhibits also polymorphic stability in comparison to the free base form or other salts as evident from Table 1.
Polymorphism refers to the ability of a solid material to exist in more than one crystal structure or solid form.
Table 1: Thermal analysis and polymorphic stability (Methods used: DSC, TGA) Form TGA Thermal stability of hydrate DSC
1xHCI 2.1% labile loss of water before melting 1xMsON 4.3% stable loss of water before melting 1xTs0H 5.9% labile loss of water before melting Free Base 8.8% labile loss of water before melting TGA: Thermogravimetric Analysis or Thermal Gravimetric Analysis DSC: Differential Scanning Calorimetry Form: refers to the mono chloride salt, the mono mesylate salt, the mono tosylate salt and the free base of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-(2-pyridinyl)phenyl]acetamide The free base form as well as the hydrochloride and tosylate salts form hydrates of low thermal and low polymorphic stability. Upon mild heating (about 50 C to 60 C), the water content is reduced which would make these salts and the free base form extremely difficult to handle and to process during production and formulation. In contrast the hydrate of the mono mesylate salt is thermally stable and polymorphic stable at much higher temperatures of considerably above 100 C as judged by TGA.
The free base of N45-(anninosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide exists in four polymorphic forms and an amorphous form at room temperature. In addition, several solvates can be detected for the free base depending on the solvent. The data currently available do not permit the identification of the thermodynamically most stable form because all batches synthesised according to prior art display more than one melting peak by differential scanning calorimetry.
The physico-chemical properties of various salts (hydrochloride HCI, mesylate Ms0H, tosylate Ts0H) as well as of the free base have been investigated and compared (see Table 2).
Moreover the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyI)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide exhibits also polymorphic stability in comparison to the free base form or other salts as evident from Table 1.
Polymorphism refers to the ability of a solid material to exist in more than one crystal structure or solid form.
Table 1: Thermal analysis and polymorphic stability (Methods used: DSC, TGA) Form TGA Thermal stability of hydrate DSC
1xHCI 2.1% labile loss of water before melting 1xMsON 4.3% stable loss of water before melting 1xTs0H 5.9% labile loss of water before melting Free Base 8.8% labile loss of water before melting TGA: Thermogravimetric Analysis or Thermal Gravimetric Analysis DSC: Differential Scanning Calorimetry Form: refers to the mono chloride salt, the mono mesylate salt, the mono tosylate salt and the free base of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-(2-pyridinyl)phenyl]acetamide The free base form as well as the hydrochloride and tosylate salts form hydrates of low thermal and low polymorphic stability. Upon mild heating (about 50 C to 60 C), the water content is reduced which would make these salts and the free base form extremely difficult to handle and to process during production and formulation. In contrast the hydrate of the mono mesylate salt is thermally stable and polymorphic stable at much higher temperatures of considerably above 100 C as judged by TGA.
The free base of N45-(anninosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide exists in four polymorphic forms and an amorphous form at room temperature. In addition, several solvates can be detected for the free base depending on the solvent. The data currently available do not permit the identification of the thermodynamically most stable form because all batches synthesised according to prior art display more than one melting peak by differential scanning calorimetry.
The physico-chemical properties of various salts (hydrochloride HCI, mesylate Ms0H, tosylate Ts0H) as well as of the free base have been investigated and compared (see Table 2).
13 Table 2. Salt screening for N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide. n.a. not applicable, n.d. not determined, HPLC
high pressure liquid chromatography, ++ very good/high + good/high, - bad/low, - - very bad/low.
Property lx 2x lx 2x lx 2x 1x Free Determined HCI HCI Ms0H Ms0H Ts0H Ts0H PhCOOH base by F Preparation inal + + + and processing crystallisation Stirring for Stability to one week at ++ ++ ++ n.a.
dissociation room temperature HPLC:
Purity +
correct stoichiometry X-ray Crystallinity n.d. + n.d n.d n.d + diffraction, ______________________________________________________________ m icroscop_y_ Water Solubility solubility 39.4 n.d 138.3 n.d 50 n.d n.d 0.2 screening (mg/100 mL) Storage at Stability to ++ n.d. ++ n.d n.d n.d ++ 90 C for one decomposition week Dihydrochloride (2xHCI), dimesylate (2xMs0H), ditosylate (2xTs0H) and benzoate (1xPhCOOH) salts of the free base of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide do not meet the criterion of stoichiometry. In addition, the hydrate of the monohydrochloride salt shows a decrease of crystallinity during storage. Furthermore, the free base and the monotosylate form hydrates with low termal stability making them unsuitable for tabletting. These results are disclosed in Table 1 above, where the polymorphic instability of the hydrochloride salt, the tosylate salt and the free base form are discussed. Thus surprisingly only the inventive mono mesylate salt exhibited the required polymorphic and thermal stabiliy in order to allow manufacture, processing and formulation especially in a pharmaceutical scale.
One possibility to prepare the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-214-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate was by dissolving the base in 10 vol ethanol / water (1:1), adding 1.15 equivalents of methanesulfonic acid at 50 ¨ 55 C during 5 ¨ 15 min, seeding with 0.5 mol A) of final product, ageing for 1 ¨ 1.5 h at 50 C and cooling to 20 ¨ 25 C during 2.5h.
After further stirring for 1h, the crystalline mesylate monohydrate was isolated by filtration and dried in vacuo, resulting in a yield of > 95%. Using this procedure, N-[5-
high pressure liquid chromatography, ++ very good/high + good/high, - bad/low, - - very bad/low.
Property lx 2x lx 2x lx 2x 1x Free Determined HCI HCI Ms0H Ms0H Ts0H Ts0H PhCOOH base by F Preparation inal + + + and processing crystallisation Stirring for Stability to one week at ++ ++ ++ n.a.
dissociation room temperature HPLC:
Purity +
correct stoichiometry X-ray Crystallinity n.d. + n.d n.d n.d + diffraction, ______________________________________________________________ m icroscop_y_ Water Solubility solubility 39.4 n.d 138.3 n.d 50 n.d n.d 0.2 screening (mg/100 mL) Storage at Stability to ++ n.d. ++ n.d n.d n.d ++ 90 C for one decomposition week Dihydrochloride (2xHCI), dimesylate (2xMs0H), ditosylate (2xTs0H) and benzoate (1xPhCOOH) salts of the free base of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide do not meet the criterion of stoichiometry. In addition, the hydrate of the monohydrochloride salt shows a decrease of crystallinity during storage. Furthermore, the free base and the monotosylate form hydrates with low termal stability making them unsuitable for tabletting. These results are disclosed in Table 1 above, where the polymorphic instability of the hydrochloride salt, the tosylate salt and the free base form are discussed. Thus surprisingly only the inventive mono mesylate salt exhibited the required polymorphic and thermal stabiliy in order to allow manufacture, processing and formulation especially in a pharmaceutical scale.
One possibility to prepare the crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-214-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate was by dissolving the base in 10 vol ethanol / water (1:1), adding 1.15 equivalents of methanesulfonic acid at 50 ¨ 55 C during 5 ¨ 15 min, seeding with 0.5 mol A) of final product, ageing for 1 ¨ 1.5 h at 50 C and cooling to 20 ¨ 25 C during 2.5h.
After further stirring for 1h, the crystalline mesylate monohydrate was isolated by filtration and dried in vacuo, resulting in a yield of > 95%. Using this procedure, N-[5-
14 (aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-244-(2-pyridiny1)-phenyl]acet-amide methanesulfonic acid monohydrate in purity >99% containing < 2ppm residual Pd could be prepared reproducibly concerning yield and purity.
Further, the crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methyl-244-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate can be prepared in a defined and stable polymorphic form and in addition the co-precipitation of the less soluble free base form is avoided applying this process. Consequently the crystalline mesylate monohydrate of the present invention is free or substantially free of free base.
The inventive crystalline mesylate monohydrate salt further shows stability (as pure API and in pharmaceutical formulations) in long term stability studies, exhibits increased release kinetics from pharmaceutical compositions and leads to improved bioavailability.
As evident from figure 2 which shows the single-crystal X-ray structure analysis of the N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate, the salt is formed between the mesylate and the protonated pyridinyl ring. Moreover, exactly one mol equivalent water is incorporated into the crystal structure wherein the hydrogen atoms of the water molecule form hydrogen bridges with oxygen atoms of two different mesylate molecules. This well-defined position in the crystal lattice (see figure 3) is verified by the fact that water is released from the crystal only at high temperature, starting at 160 C. Thus the inventive compound is a definite mono mesylate and mono hydrtate of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]-acetamide.
The crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate according to the invention is a useful compound for the preparation of a pharmaceutical composition for treatment and/or prophylaxis of herpes virus infections and/or prevention of transmission of a herpes virus or herpes viruses. Pharmacokinetic data derived from single and multiple dose applications in healthy volunteers exhibited favourable plasma concentration over time profiles with long lasting half lives indicative for an once daily dosing regimen or less frequent such as once weelky. The plasma concentrations in humans exceeded those reached in in vivo and in vitro experiments sufficient to effectively treat herpes simplex virus infections in various animal models and to prevent viral replication in cell culture.
Surprisingly it was found that crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate is highly active against herpes viruses and infections caused by herpes viruses, mainly herpes simplex viruses.
Therefore the inventive crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate is especially useful for the treatment and/or prophylaxis of diseases, which 5 are caused by herpes simplex viruses, and/or prevention of transmission of a herpes virus or herpes viruses.
Infections with herpes simplex viruses (HSV, subtype 1 and 2) are categorized into one of several distinct disorders based on the site of infection.
Orofacial herpes virus infection, the visible symptoms of which are colloquially called cold sores or fever blisters, infects the face and mouth.
Orofacial herpes is the most common form of infection.
Genital herpes is the second common form of a herpes simplex virus infection.
Although genital herpes is largely believed to be caused by HSV-2 only, genital HSV-1 infections are increasing. Other disorders such as herpetic whitlow,
Further, the crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methyl-244-(2-pyridiny1)-phenyllacetamide methanesulfonic acid monohydrate can be prepared in a defined and stable polymorphic form and in addition the co-precipitation of the less soluble free base form is avoided applying this process. Consequently the crystalline mesylate monohydrate of the present invention is free or substantially free of free base.
The inventive crystalline mesylate monohydrate salt further shows stability (as pure API and in pharmaceutical formulations) in long term stability studies, exhibits increased release kinetics from pharmaceutical compositions and leads to improved bioavailability.
As evident from figure 2 which shows the single-crystal X-ray structure analysis of the N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)pheny1]-acetamide methanesulfonic acid monohydrate, the salt is formed between the mesylate and the protonated pyridinyl ring. Moreover, exactly one mol equivalent water is incorporated into the crystal structure wherein the hydrogen atoms of the water molecule form hydrogen bridges with oxygen atoms of two different mesylate molecules. This well-defined position in the crystal lattice (see figure 3) is verified by the fact that water is released from the crystal only at high temperature, starting at 160 C. Thus the inventive compound is a definite mono mesylate and mono hydrtate of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]-acetamide.
The crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate according to the invention is a useful compound for the preparation of a pharmaceutical composition for treatment and/or prophylaxis of herpes virus infections and/or prevention of transmission of a herpes virus or herpes viruses. Pharmacokinetic data derived from single and multiple dose applications in healthy volunteers exhibited favourable plasma concentration over time profiles with long lasting half lives indicative for an once daily dosing regimen or less frequent such as once weelky. The plasma concentrations in humans exceeded those reached in in vivo and in vitro experiments sufficient to effectively treat herpes simplex virus infections in various animal models and to prevent viral replication in cell culture.
Surprisingly it was found that crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate is highly active against herpes viruses and infections caused by herpes viruses, mainly herpes simplex viruses.
Therefore the inventive crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate is especially useful for the treatment and/or prophylaxis of diseases, which 5 are caused by herpes simplex viruses, and/or prevention of transmission of a herpes virus or herpes viruses.
Infections with herpes simplex viruses (HSV, subtype 1 and 2) are categorized into one of several distinct disorders based on the site of infection.
Orofacial herpes virus infection, the visible symptoms of which are colloquially called cold sores or fever blisters, infects the face and mouth.
Orofacial herpes is the most common form of infection.
Genital herpes is the second common form of a herpes simplex virus infection.
Although genital herpes is largely believed to be caused by HSV-2 only, genital HSV-1 infections are increasing. Other disorders such as herpetic whitlow,
15 herpes gladiatorum, ocular herpes (keratitis), cerebral herpes infection encephalitis, Mollaret's meningitis, neonatal herpes, and possibly Bell's palsy are also caused by herpes simplex viruses.
Further, the present invention relates to crystalline N15-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-2-(4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate in combination with an anti-inflammatory agent. Especially preferred is a combination of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate and acetylsalicylic acid.
Furthermore, the present invention relates to crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate in combination with an anti-viral agent. The further anti-viral agent is preferably an antimetabolite and most preferably a nucleobase analogues, nucleotide analogues or nucleoside analogue drug. It is further preferred if the further anti-viral agent is useful against herpes viruses and/or against transmission of a herpes virus or herpes viruses and is selected from the group of drugs comprising but not limited to or consisting of: trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir or penciclovir or the respective prodrugs valaciclovir or famciclovir. Most preferred is a corn bination of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyI)-phenyl]-acetamide methanesulfonic acid monohydrate and aciclovir or penciclovir or the respective prodrugs valaciclovir and famciclovir.
Further, the present invention relates to crystalline N15-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-2-(4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate in combination with an anti-inflammatory agent. Especially preferred is a combination of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate and acetylsalicylic acid.
Furthermore, the present invention relates to crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate in combination with an anti-viral agent. The further anti-viral agent is preferably an antimetabolite and most preferably a nucleobase analogues, nucleotide analogues or nucleoside analogue drug. It is further preferred if the further anti-viral agent is useful against herpes viruses and/or against transmission of a herpes virus or herpes viruses and is selected from the group of drugs comprising but not limited to or consisting of: trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir or penciclovir or the respective prodrugs valaciclovir or famciclovir. Most preferred is a corn bination of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyI)-phenyl]-acetamide methanesulfonic acid monohydrate and aciclovir or penciclovir or the respective prodrugs valaciclovir and famciclovir.
16 The combination of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyliacetamide methanesulfonic acid monohydrate and a further active agent (like anti-inflammatory, immunomodulatory, or anti-viral agents, e.g.
therapeutic vaccines, siRNAs, antisense oligonucleotides, nanoparticles or virus uptake inhibitors such as n-docosanol) may be administered simultaneously in one single pharmaceutical composition or in more than one pharmaceutical composition, wherein each composition comprises at least one active agent.
The inventive compound is preferably used for the production of a pharmaceutical composition containing crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent. The crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]
acetamide methanesulfonic acid monohydrate used is free or substantially free of the free base form of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl) phenyl]acetamide.
The pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluents and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way. Preferred preparations may be adapted for oral application. These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, liposomal formulations, micro-and nano-formulations, powders and deposits.
The pharmaceutical compositions according to the invention preferably comprises 5 to 70% more preferably 10 to 30% by weight crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate (all percentage data are percentages by weight based on the weight of the pharmaceutical preparations). The pharmaceutical composition comprises usually 2 to 600 mg of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate, preferably 5 to 500 mg, more preferably 10 to 300 mg and particularly preferably 20 to 200 mg based on a single dosage. The pharmaceutical composition according to the invention optionally comprises one or more filler which are for example selected from the group consisting of:
microcrystalline cellulose, fiber cellulose, calcium phosphates and mannitol.
Preferably according to the invention microcrystalline cellulose and mannitol is used.
The pharmaceutical composition expediently comprises 20 to 80%, preferably 40 to 80%, particularly preferably 45 to 70% microcrystalline cellulose and 1 to 40%, preferably 5 to
therapeutic vaccines, siRNAs, antisense oligonucleotides, nanoparticles or virus uptake inhibitors such as n-docosanol) may be administered simultaneously in one single pharmaceutical composition or in more than one pharmaceutical composition, wherein each composition comprises at least one active agent.
The inventive compound is preferably used for the production of a pharmaceutical composition containing crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate together with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent. The crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]
acetamide methanesulfonic acid monohydrate used is free or substantially free of the free base form of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl) phenyl]acetamide.
The pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluents and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way. Preferred preparations may be adapted for oral application. These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, liposomal formulations, micro-and nano-formulations, powders and deposits.
The pharmaceutical compositions according to the invention preferably comprises 5 to 70% more preferably 10 to 30% by weight crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate (all percentage data are percentages by weight based on the weight of the pharmaceutical preparations). The pharmaceutical composition comprises usually 2 to 600 mg of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methane-sulfonic acid monohydrate, preferably 5 to 500 mg, more preferably 10 to 300 mg and particularly preferably 20 to 200 mg based on a single dosage. The pharmaceutical composition according to the invention optionally comprises one or more filler which are for example selected from the group consisting of:
microcrystalline cellulose, fiber cellulose, calcium phosphates and mannitol.
Preferably according to the invention microcrystalline cellulose and mannitol is used.
The pharmaceutical composition expediently comprises 20 to 80%, preferably 40 to 80%, particularly preferably 45 to 70% microcrystalline cellulose and 1 to 40%, preferably 5 to
17 30%, particularly preferably 10 to 20% mannitol. The pharmaceutical preparation according to the invention may comprise at least one disintegration auxiliary which is for example selected from the group consisting of starch, pre-gelatinized starch, starch glycolates, cross-linked polyvinylpyrrolidone, sodium carboxymethylcellulose (=croscarmellose sodium) and other salts of carboxymethylcellulose. A mixture of two disintegration agents can also be used.
According to the invention the use of croscarmellose sodium is preferred. The pharmaceutical composition expediently comprises 3 to 35%, preferably 5 to 30% and particularly preferably 5 to 10%
of the disintegration auxiliary(ies). The pharmaceutical preparation of the invention may comprise at least one lubricant selected from the group consisting of fatty acids and their salts. According to the invention the use of magnesium stearate is particularly preferred.
The pharmaceutical composition of the invention may comprise a flow agent which could be colloidas anhydrous silica or talcum powder. According to the invention the use of Colloidas anhydrous silica is particularly preferred. The flow agent is expediently used in an amount of 0.3 to 2.0%, particularly preferably from 0.4 to 1.5% and most preferably from 0.5 to 1%.
A particularly preferred pharmaceutical composition of the invention comprises:
5% ¨ 30% crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridinyl)phenyl]acetamide methane-sulfonic acid monohydrate, 5% ¨ 10%
croscarmellose-sodium, 0.5 ¨ 0.7% magnesium stearate, 40% ¨ 70%
microcrystalline cellulose, 10% ¨20% mannitol and 0.5% ¨ 1% colloidal anhydrous silica.
The pharmaceutical compositions according to the invention can be administered to a patient in need thereof once daily at a once daily dose of about 20 to 750 mg of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1}-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonic acid monohydrate. The pharmaceutical compositions according to the invention can also be administered to a patient in need thereof thrice daily, twice daily, once daily, thrice weekly, twice weekly, or once weekly.
The administration on a thrice weekly, twice weekly, or once weekly basis is preferred and especially preferred is a once weekly administration, i.e. an administration one time a week of a pharmaceutical composition containing between 400 mg to 600 mg of the inventive N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acet-amide methanesulfonic acid monohydrate. Moreover it is preferred to start the administration of the mesylate monohydrate of the present invention with a high loading dose, for instance, with an initial single dose of 400 mg to 800 mg and to
According to the invention the use of croscarmellose sodium is preferred. The pharmaceutical composition expediently comprises 3 to 35%, preferably 5 to 30% and particularly preferably 5 to 10%
of the disintegration auxiliary(ies). The pharmaceutical preparation of the invention may comprise at least one lubricant selected from the group consisting of fatty acids and their salts. According to the invention the use of magnesium stearate is particularly preferred.
The pharmaceutical composition of the invention may comprise a flow agent which could be colloidas anhydrous silica or talcum powder. According to the invention the use of Colloidas anhydrous silica is particularly preferred. The flow agent is expediently used in an amount of 0.3 to 2.0%, particularly preferably from 0.4 to 1.5% and most preferably from 0.5 to 1%.
A particularly preferred pharmaceutical composition of the invention comprises:
5% ¨ 30% crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-244-(2-pyridinyl)phenyl]acetamide methane-sulfonic acid monohydrate, 5% ¨ 10%
croscarmellose-sodium, 0.5 ¨ 0.7% magnesium stearate, 40% ¨ 70%
microcrystalline cellulose, 10% ¨20% mannitol and 0.5% ¨ 1% colloidal anhydrous silica.
The pharmaceutical compositions according to the invention can be administered to a patient in need thereof once daily at a once daily dose of about 20 to 750 mg of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1}-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonic acid monohydrate. The pharmaceutical compositions according to the invention can also be administered to a patient in need thereof thrice daily, twice daily, once daily, thrice weekly, twice weekly, or once weekly.
The administration on a thrice weekly, twice weekly, or once weekly basis is preferred and especially preferred is a once weekly administration, i.e. an administration one time a week of a pharmaceutical composition containing between 400 mg to 600 mg of the inventive N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acet-amide methanesulfonic acid monohydrate. Moreover it is preferred to start the administration of the mesylate monohydrate of the present invention with a high loading dose, for instance, with an initial single dose of 400 mg to 800 mg and to
18 continue the administration with a lower dose of 100 mg to 150 mg per day or per week over the period of treatment.
Furthermore, the present invention also includes pharmaceutical compositions for the preferred parenteral application. Further ways of administration are dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application. The administered pharmaceutical compositions contain in addition to typical vehicles and/or diluents crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate as active ingredient.
Further preferred are topical formulations of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyljacetamide methanesulfonic acid monohydrate for dermal or transdermal application. Preferred topical formulations are skin creams, skin lotions, emulsions, gels, suspensions, ointments, oils, lip sticks and balms.
The formulation may be added any conventional carriers, adjuvants and optionally other ingredients. Preferred auxiliaries originate from the group comprising or consisting of:
preservatives, antioxidants, stabilizers, solubilizers and odors.
Ointments, pastes, creams and gels may include at least one conventional carriers, for example animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.
Solutions and emulsions may include conventional carriers such as solvents, solubilizing agents and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, particularly cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
Suspensions may include conventional carriers such as liquid diluents, for example water, ethanol or propylene glycol, suspending agents, e.g. ethoxylated isostearyl alcohols, polyoxyethylene and polyoxyethylene sorbitan esters, microcrystalline cellulose, bentonite, agar-agar and tragacanth or mixtures of these substances.
An inventive composition may contain lipid particles in which crystalline N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyl]acetamide
Furthermore, the present invention also includes pharmaceutical compositions for the preferred parenteral application. Further ways of administration are dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application. The administered pharmaceutical compositions contain in addition to typical vehicles and/or diluents crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate as active ingredient.
Further preferred are topical formulations of crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyljacetamide methanesulfonic acid monohydrate for dermal or transdermal application. Preferred topical formulations are skin creams, skin lotions, emulsions, gels, suspensions, ointments, oils, lip sticks and balms.
The formulation may be added any conventional carriers, adjuvants and optionally other ingredients. Preferred auxiliaries originate from the group comprising or consisting of:
preservatives, antioxidants, stabilizers, solubilizers and odors.
Ointments, pastes, creams and gels may include at least one conventional carriers, for example animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.
Solutions and emulsions may include conventional carriers such as solvents, solubilizing agents and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, particularly cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
Suspensions may include conventional carriers such as liquid diluents, for example water, ethanol or propylene glycol, suspending agents, e.g. ethoxylated isostearyl alcohols, polyoxyethylene and polyoxyethylene sorbitan esters, microcrystalline cellulose, bentonite, agar-agar and tragacanth or mixtures of these substances.
An inventive composition may contain lipid particles in which crystalline N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-y1]-N-methy1-244-(2-pyridiny1)-phenyl]acetamide
19 methanesulfonic acid monohydrate is transported. The formulation of the pharmaceutical composition may also contain adjuvants, which are usually used in this type of composition, such as thickeners, emollients, humectants, surfactants, emulsifiers, preservatives, anti-foaming, perfumes, waxes, lanolin, propellants and dyes.
The inventive pharmaceutical composition may also be present as an alcoholic gel which comprises crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate and one or more lower alcohols or lower polyols, such as ethanol, propylene glycol or glycerol, and a thickening agent, such as siliceous earth. The oily-alcoholic gels also comprise natural or synthetic oil or wax. Gels may also contain organic thickeners, such as Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickeners, such as aluminum silicates such as bentonite or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
An inventive pharmaceutical composition may contain the following preservatives:
phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid.
As pharmaceutically acceptable carrier, excipient and/or diluents can be used carriers such as preferably an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules); suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes, sugars such as sucrose, starches derived from wheat corn rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate; lubricants such as boric acid, sodium benzoate, sodium acetate, sodium chloride, magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine; disintegrating agents (disintegrates) such as starch, methylcellulose, guar gum, modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and
The inventive pharmaceutical composition may also be present as an alcoholic gel which comprises crystalline N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y11-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate and one or more lower alcohols or lower polyols, such as ethanol, propylene glycol or glycerol, and a thickening agent, such as siliceous earth. The oily-alcoholic gels also comprise natural or synthetic oil or wax. Gels may also contain organic thickeners, such as Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickeners, such as aluminum silicates such as bentonite or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
An inventive pharmaceutical composition may contain the following preservatives:
phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid.
As pharmaceutically acceptable carrier, excipient and/or diluents can be used carriers such as preferably an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules); suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes, sugars such as sucrose, starches derived from wheat corn rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate; lubricants such as boric acid, sodium benzoate, sodium acetate, sodium chloride, magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine; disintegrating agents (disintegrates) such as starch, methylcellulose, guar gum, modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and
20 cross-linked microcrystalline celluloses such as sodium croscaramellose, alginates such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures;
coloring agents, sweetening agents, flavoring agents, preservatives; glidents are for example silicon dioxide and talc; suitable adsorbent are clay, aluminum oxide, suitable diluents are water or water/propylene glycol solutions for parenteral injections, juice, sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn rice, and potato, and celluloses such as microcrystalline cellulose.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description.
Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention.
EXAMPLES
Definition: As used herein, the term "1 vol." refers to 1 L per kg of the respective starting material (1 vol. = 1 L per kg of the respective material or starting material).
Example 1: Synthesis of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonate monohydrate
coloring agents, sweetening agents, flavoring agents, preservatives; glidents are for example silicon dioxide and talc; suitable adsorbent are clay, aluminum oxide, suitable diluents are water or water/propylene glycol solutions for parenteral injections, juice, sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn rice, and potato, and celluloses such as microcrystalline cellulose.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description.
Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention.
EXAMPLES
Definition: As used herein, the term "1 vol." refers to 1 L per kg of the respective starting material (1 vol. = 1 L per kg of the respective material or starting material).
Example 1: Synthesis of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonate monohydrate
21 Step 1 (Suzuki-Miyaura coupling and saponification) The inertized reactor is charged with bis(triphenylphosphine)palladium(II) chloride (0.010 eq.) and reinertized. Then, toluene (1.65 vol.) is added. After heating to 40 C, triethylamine (3.00 eq.) is added. A solution of ethyl-4-bromophenylacetate (1.00 eq.) in toluene (0.82 vol.) is added. The resulting suspension is heated to 90-95 C
prior to dosing pinacol borane (1.30 eq.) over a period of 60-90 min. Stirring at 90-95 C is continued for at least 2 more h before conversion is checked by HPLC. After cooling to C, 2-chloropyridine (1.00 eq.) is charged to the reaction mixture. Then, 30%
NaOH
(6.00 eq.) is added followed by heating to 55-60 C.
Stirring at this temperature is 10 continued for at least 4 h before conversion is checked by HPLC. Once conversion is deemed complete, the reaction mixture is concentrated at about 300 mbar until 0.8 vol.
of distillate have been collected. The reaction mixture is diluted with water (2.72 vol.), cooled to 20 C and the phases are separated. The organic layer is discarded, while the pH of the aqueous layer is adjusted to pH 1 by addition of 33% HCI at 20 C.
MIBK (2.30 vol.) and Celitee (165 g/kg) are added and the resulting mixture is stirred for at least 15 min at 20 C before the solids are removed by filtration. The reactor and the filter cake are rinsed successively with water and the combined filtrate is transferred back into the reactor. The phases are separated and the aqueous layer is washed twice more with MIBK. After dilution with water, the aqueous acidic product solution was heated to 55 C
and filtered through a plug packed with Celite0 at the bottom and activated charcoal on top. The Celite&charcoal plug was washed once more with pre-heated water (0.5 vol., 55 C) and the combined filtrate was charged back into the reactor. At 20 C, the pH was adjusted to ¨3.0 by addition of 30% NaOH before the product solution was heated to 60 C. More NaOH was dosed to adjust the pH to 4.1-4.3. The resulting suspension was stirred for 1-1.5 h at 60 C prior to being cooled to 20 C. After additional stirring for at least 1 h at this temperature, the product was filtered, washed twice with water, pre-dried in a flow of N2 and finally dried in vacuo at 50-65 C. Typical yield: 38-42%.
Step 2 (amide coupling) The reactor is charged with product from step 1 (1.00 eq.) and 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide (1.02 eq.). THE
(7.08 vol.) and NMP (1.11 vol.) are added. The resulting suspension is cooled to 0 C prior to adding 1-ethy1-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (1.23 eq.) in 4 equal portions over a period of > 90 min. After at least 2 more h at 0 C, the reaction mixture is warmed to 20 C. At this temperature, stirring is continued for additional 2 h before conversion is checked by HPLC. Then, at 10-15 C about 2% (0.2 vol.) of the reaction mixture are added to water (12.3 vol) within at least 5 min. The resulting thin suspension is stirred
prior to dosing pinacol borane (1.30 eq.) over a period of 60-90 min. Stirring at 90-95 C is continued for at least 2 more h before conversion is checked by HPLC. After cooling to C, 2-chloropyridine (1.00 eq.) is charged to the reaction mixture. Then, 30%
NaOH
(6.00 eq.) is added followed by heating to 55-60 C.
Stirring at this temperature is 10 continued for at least 4 h before conversion is checked by HPLC. Once conversion is deemed complete, the reaction mixture is concentrated at about 300 mbar until 0.8 vol.
of distillate have been collected. The reaction mixture is diluted with water (2.72 vol.), cooled to 20 C and the phases are separated. The organic layer is discarded, while the pH of the aqueous layer is adjusted to pH 1 by addition of 33% HCI at 20 C.
MIBK (2.30 vol.) and Celitee (165 g/kg) are added and the resulting mixture is stirred for at least 15 min at 20 C before the solids are removed by filtration. The reactor and the filter cake are rinsed successively with water and the combined filtrate is transferred back into the reactor. The phases are separated and the aqueous layer is washed twice more with MIBK. After dilution with water, the aqueous acidic product solution was heated to 55 C
and filtered through a plug packed with Celite0 at the bottom and activated charcoal on top. The Celite&charcoal plug was washed once more with pre-heated water (0.5 vol., 55 C) and the combined filtrate was charged back into the reactor. At 20 C, the pH was adjusted to ¨3.0 by addition of 30% NaOH before the product solution was heated to 60 C. More NaOH was dosed to adjust the pH to 4.1-4.3. The resulting suspension was stirred for 1-1.5 h at 60 C prior to being cooled to 20 C. After additional stirring for at least 1 h at this temperature, the product was filtered, washed twice with water, pre-dried in a flow of N2 and finally dried in vacuo at 50-65 C. Typical yield: 38-42%.
Step 2 (amide coupling) The reactor is charged with product from step 1 (1.00 eq.) and 4-methy1-2-(methylamino)-1,3-thiazole-5-sulfonamide (1.02 eq.). THE
(7.08 vol.) and NMP (1.11 vol.) are added. The resulting suspension is cooled to 0 C prior to adding 1-ethy1-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (1.23 eq.) in 4 equal portions over a period of > 90 min. After at least 2 more h at 0 C, the reaction mixture is warmed to 20 C. At this temperature, stirring is continued for additional 2 h before conversion is checked by HPLC. Then, at 10-15 C about 2% (0.2 vol.) of the reaction mixture are added to water (12.3 vol) within at least 5 min. The resulting thin suspension is stirred
22 at 10-15 C for at least 1 h prior to dosage of the remaining bulk of the reaction mixture over > 4 h.
Stirring at 10-15 C is continued for at least 0.5 h before the solids are filtered off, washed with water and dried on a nutsche filter in a steady flow of N2 until deemed sufficiently dry (LOD <45 % w/w; LOD: Loss on drying).
The feed reactor is charged with the crude product, THF (8.15 vol.), and water (up to 1.17 vol. depending on LOD of crude product). The resulting suspension is heated to 60-65 C and stirred for 1 h at this temperature. An almost clear solution is obtained which is subjected to polish filtration using a heatable lense filter heated to 60 C. The feed reactor, the transfer lines and the filter are successively rinsed with a mixture of THF (0.44 vol.) and purified water (0.06 vol.) at 60-65 C. The combined filtrate is collected in a separate reactor and heated to 50-55 C. To the reactor content, water (3.23 vol.) is dosed over at least 30 min. Stirring at 50-55 C is continued for 1-1.5 h before another portion of water (8.93 vol.) is slowly added within 2 h. After stirring for 1-1.5 h at 50 C, the resulting suspension is cooled to 5 C over 2.5 h and stirred for further 0.5 h. Then, the solids are filtered off, washed with water (3 x 2.96 vol.) and pre-dried on the nutsche filter in a steady flow of N2. Final drying is accomplished in vacuo at 50-65 C using a conical drier. Typical yield: 78-83%.
Step 3 (Salt Formation) The reactor is charged with product from step 2 (1.00 eq.), ethanol (4.96 vol.) and water (4.96 vol.). After heating the resulting suspension to 50-55 C, methanesulfonic acid (1.15 eq.) is added within < 15 min.
Complete dissolution of starting materials is typically observed at the very end of addition. Immediately within the next 5 min, stirring is reduced to the minimum acceptable rate and the reaction mixture is seeded with N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonate monohydrate (0.005 eq.) which was prepared in the desired polymorphic form in a preceding experiment. Slow stirring at 50-55 C is continued for 60-90 min prior to cooling to 20-25 C during > 2.5 h. After stirring for 1 more h, the solids are filtered off, washed with ethanol/water 5:2 VN (3.10 vol.), pre-dried in a nitrogen flow and transferred into a conical drier for final drying in vacuo at 20-60 C.
Typical yield: >95%.
Example 2:
Tablet comprising 60 mg of N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-yl]-N-methy1-2-[4-(2-pyridinyl)-phenyljacetamide (calculated as free base form) according to the invention as micronized active compound, content of active compound about 59% (based on an unvarnished tablet):
Stirring at 10-15 C is continued for at least 0.5 h before the solids are filtered off, washed with water and dried on a nutsche filter in a steady flow of N2 until deemed sufficiently dry (LOD <45 % w/w; LOD: Loss on drying).
The feed reactor is charged with the crude product, THF (8.15 vol.), and water (up to 1.17 vol. depending on LOD of crude product). The resulting suspension is heated to 60-65 C and stirred for 1 h at this temperature. An almost clear solution is obtained which is subjected to polish filtration using a heatable lense filter heated to 60 C. The feed reactor, the transfer lines and the filter are successively rinsed with a mixture of THF (0.44 vol.) and purified water (0.06 vol.) at 60-65 C. The combined filtrate is collected in a separate reactor and heated to 50-55 C. To the reactor content, water (3.23 vol.) is dosed over at least 30 min. Stirring at 50-55 C is continued for 1-1.5 h before another portion of water (8.93 vol.) is slowly added within 2 h. After stirring for 1-1.5 h at 50 C, the resulting suspension is cooled to 5 C over 2.5 h and stirred for further 0.5 h. Then, the solids are filtered off, washed with water (3 x 2.96 vol.) and pre-dried on the nutsche filter in a steady flow of N2. Final drying is accomplished in vacuo at 50-65 C using a conical drier. Typical yield: 78-83%.
Step 3 (Salt Formation) The reactor is charged with product from step 2 (1.00 eq.), ethanol (4.96 vol.) and water (4.96 vol.). After heating the resulting suspension to 50-55 C, methanesulfonic acid (1.15 eq.) is added within < 15 min.
Complete dissolution of starting materials is typically observed at the very end of addition. Immediately within the next 5 min, stirring is reduced to the minimum acceptable rate and the reaction mixture is seeded with N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyliacetamide methanesulfonate monohydrate (0.005 eq.) which was prepared in the desired polymorphic form in a preceding experiment. Slow stirring at 50-55 C is continued for 60-90 min prior to cooling to 20-25 C during > 2.5 h. After stirring for 1 more h, the solids are filtered off, washed with ethanol/water 5:2 VN (3.10 vol.), pre-dried in a nitrogen flow and transferred into a conical drier for final drying in vacuo at 20-60 C.
Typical yield: >95%.
Example 2:
Tablet comprising 60 mg of N-[5-(aminosulfony1)-4-methy1-1,3-thiazol-2-yl]-N-methy1-2-[4-(2-pyridinyl)-phenyljacetamide (calculated as free base form) according to the invention as micronized active compound, content of active compound about 59% (based on an unvarnished tablet):
23 crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, 77.0 mg AvicelO PH 101 118.0 mg Lactose, fine 40.0 mg Ac-Di-Sol 20.0 mg Polyinylpyrrolidone 25 10.0 mg Magnesium stearate 2.0 mg Example 3:
Ointment comprising 30 mg of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 38.4 mg zinc oxide 60.0 mg talcum 60.0 mg glycerol 120.0 mg propyleneglycole 40.0 mg sterile water 80.0 mg Example 4:
Gel comprising 40 mg of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound.
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 51.2 mg solution of sodium hydroxide 30.0 mg 1,2-propandiol 80.0 mg glycerol 20.0 mg polyacrylic acid 60.0 mg sterile water 280.0 mg
Ointment comprising 30 mg of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 38.4 mg zinc oxide 60.0 mg talcum 60.0 mg glycerol 120.0 mg propyleneglycole 40.0 mg sterile water 80.0 mg Example 4:
Gel comprising 40 mg of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound.
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 51.2 mg solution of sodium hydroxide 30.0 mg 1,2-propandiol 80.0 mg glycerol 20.0 mg polyacrylic acid 60.0 mg sterile water 280.0 mg
24 Example 5:
Gel comprising 40 mg of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyllacetamide (calculated as free base form) according to the invention as micronized active compound.
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 51.2 mg 1,2-propandiol 80.0 mg glycerol 20.0 mg polyacrylic acid 60.0 mg sterile water 280.0 mg Example 6:
Tablet comprising 50 mg of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound, content of active compound about 59% (based on an unvarnished tablet):
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 64.00 mg Polyinylpyrrolidone 25 3.50 mg Microcrystalline cellulose 20.00 mg Croscamellose sodium 10.00 mg Magnesium stearate 0.85 mg optionally HPMC film coating 3.00 mg Example 7:
Crystal structure of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate Formula C19H24N407S3, M = 516.62, F(000) = 540, colorless plate, size 0.02 = 0.13 = 0.15 mm3, triclinic, space group P -1 , Z
= 2, a =
9.4908(7)A, b = 9.5545(7) A, c = 14.4137(9) A, a = 86.130(3) , 13 = 72.104(3) , v=
68.253(4) , V = 1153.68(15) A3, Dcaic = 1.487 Mg m-3. The crystal was measured on a Nonius KappaCCD diffractometer at 293K using graphite-monochromated Mo K,-
Gel comprising 40 mg of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyllacetamide (calculated as free base form) according to the invention as micronized active compound.
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 51.2 mg 1,2-propandiol 80.0 mg glycerol 20.0 mg polyacrylic acid 60.0 mg sterile water 280.0 mg Example 6:
Tablet comprising 50 mg of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridiny1)-phenyl]acetamide (calculated as free base form) according to the invention as micronized active compound, content of active compound about 59% (based on an unvarnished tablet):
crystalline N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridiny1)-phenyl]acetamide methanesulfonic acid monohydrate, micronized 64.00 mg Polyinylpyrrolidone 25 3.50 mg Microcrystalline cellulose 20.00 mg Croscamellose sodium 10.00 mg Magnesium stearate 0.85 mg optionally HPMC film coating 3.00 mg Example 7:
Crystal structure of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate Formula C19H24N407S3, M = 516.62, F(000) = 540, colorless plate, size 0.02 = 0.13 = 0.15 mm3, triclinic, space group P -1 , Z
= 2, a =
9.4908(7)A, b = 9.5545(7) A, c = 14.4137(9) A, a = 86.130(3) , 13 = 72.104(3) , v=
68.253(4) , V = 1153.68(15) A3, Dcaic = 1.487 Mg m-3. The crystal was measured on a Nonius KappaCCD diffractometer at 293K using graphite-monochromated Mo K,-
25 radiation with A = 0.71073 A, =
30.065 . Minimal/maximal transmission 0.95/0.99, p = 0.370 mm-1. The COLLECT suite has been used for datacollection and integration.
From a total of 43492 reflections, 6761 were independent (merging r = 0.026).
From these, 4955 were considered as observed (1>3.0cr(I)) and were used to refine parameters. The structure was solved by direct methods using the program SIR92.
Least-squares refinement against F was carried out on all non-hydrogen atoms using the program CRYSTALS. R = 0.0313 (observed data), wR = 0.0432 (all data), GOF =
1.0736. Minimal/maximal residual electron density = -0.28/0.33 e k3.
Chebychev polynomial weights were used to complete the refinement.
Single-crystal structure parameters for N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyllacetamide methanesulfonic acid monohydrate are shown in Table 1A.
Characteristic peaks of batch BXR3NC1 obtained by X-ray powder diffraction analysis are shown in Table 3.
Table 3: Characteristic peaks of batch BXR3NC1 obtained by X-ray powder diffraction analysis (Cu Kalpha irradiation).
Angle d value (2-Theta ) (Angstrom) 6.5 13.7 12.9 6.8 16.8 5.29 18.9 4.70 19.3 4.61 19.5 4.56 20.0 4.44 22.4 3.97 22.6 3.94 23.2 3.84 23.8 3.74 25.5 3.49 25.9 3.43 28.8 3.10 30.5 2.93 32.7 2.74 35.7 2.51 The 2-Theta values are rounded to 1 decimal place due to a normal deviation of +/- 0.1
30.065 . Minimal/maximal transmission 0.95/0.99, p = 0.370 mm-1. The COLLECT suite has been used for datacollection and integration.
From a total of 43492 reflections, 6761 were independent (merging r = 0.026).
From these, 4955 were considered as observed (1>3.0cr(I)) and were used to refine parameters. The structure was solved by direct methods using the program SIR92.
Least-squares refinement against F was carried out on all non-hydrogen atoms using the program CRYSTALS. R = 0.0313 (observed data), wR = 0.0432 (all data), GOF =
1.0736. Minimal/maximal residual electron density = -0.28/0.33 e k3.
Chebychev polynomial weights were used to complete the refinement.
Single-crystal structure parameters for N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyllacetamide methanesulfonic acid monohydrate are shown in Table 1A.
Characteristic peaks of batch BXR3NC1 obtained by X-ray powder diffraction analysis are shown in Table 3.
Table 3: Characteristic peaks of batch BXR3NC1 obtained by X-ray powder diffraction analysis (Cu Kalpha irradiation).
Angle d value (2-Theta ) (Angstrom) 6.5 13.7 12.9 6.8 16.8 5.29 18.9 4.70 19.3 4.61 19.5 4.56 20.0 4.44 22.4 3.97 22.6 3.94 23.2 3.84 23.8 3.74 25.5 3.49 25.9 3.43 28.8 3.10 30.5 2.93 32.7 2.74 35.7 2.51 The 2-Theta values are rounded to 1 decimal place due to a normal deviation of +/- 0.1
26 Example 8:
The exposure of rats to N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a repeated dose 13-week toxicity study performed with the free base N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide (free base) was compared to the exposures observed in a 26-week repeated dose toxicity study performed with the mesylate monohydrate. In both studies, the test items were administered as 0.5% (w/v) tylose suspensions, and the concentrations were adjusted to the equivalents of free base N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-244-(2-pyridinyl)phenyliacetamide.
Exposures were comparable after administration of 10, 50 and 250 mg/kg/day both after administration of the first dose (days 1, 2; Table 4), as well as after repeated dose administration for 13 weeks (Table 5). There was an indication of a possibly higher exposure after a dose of 10 mg/kg/day. Of note was the observation that exposures after administration of N45-(anninosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate were higher, after doses of 50 and 250 mg/kg/day (adjusted to the equivalents of free base), as compared to exposures after administration of the free base. The extent of exposure increased by up to 2.7-fold for Crna, and 4-fold for AUC. It is concluded that N-15-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-244-(2-pyridinyl)phenyl]acetamide mesylate monohydrate gave rise to higher exposures as compared to those observed following administration of equimolecular doses (50 and 250 mg/kg/day) of free base equivalents of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide. Such a major increase in the extent of exposure is thus indicative of the mesylate salts improved physicochemical properties giving rise to a more favourable dissolution profile with concomitant increase in systemic exposure relative to that observed following administration of the freebase.
This enhancement in exposure, following administration of the mesylate salt, therefore means that a higher exposure to the active ingredient is achieved giving rise to a greater efficacy and higher viral resistance barrier, both regarded as an essential feature for the treatment of viral infections. The enhancement of both efficacy and resistance barrier are judged to be prime features associated with the mesylate salt formulation Table 4: Comparison of exposures in the 13-week toxicity (free base) and the 26-week toxicity (mesylate salt) studies in rats after one administration. M male, F
female. Cmox is the maximal observed analyte concentration; AUC(0-24) is defined as the area under the analyte vs. time concentration up to 24 hours post dosing; calculated by linear up/In down summation
The exposure of rats to N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a repeated dose 13-week toxicity study performed with the free base N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide (free base) was compared to the exposures observed in a 26-week repeated dose toxicity study performed with the mesylate monohydrate. In both studies, the test items were administered as 0.5% (w/v) tylose suspensions, and the concentrations were adjusted to the equivalents of free base N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-yli-N-methyl-244-(2-pyridinyl)phenyliacetamide.
Exposures were comparable after administration of 10, 50 and 250 mg/kg/day both after administration of the first dose (days 1, 2; Table 4), as well as after repeated dose administration for 13 weeks (Table 5). There was an indication of a possibly higher exposure after a dose of 10 mg/kg/day. Of note was the observation that exposures after administration of N45-(anninosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate were higher, after doses of 50 and 250 mg/kg/day (adjusted to the equivalents of free base), as compared to exposures after administration of the free base. The extent of exposure increased by up to 2.7-fold for Crna, and 4-fold for AUC. It is concluded that N-15-(aminosulfony1)-4-methyl-1,3-thiazol-2-yll-N-methyl-244-(2-pyridinyl)phenyl]acetamide mesylate monohydrate gave rise to higher exposures as compared to those observed following administration of equimolecular doses (50 and 250 mg/kg/day) of free base equivalents of N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide. Such a major increase in the extent of exposure is thus indicative of the mesylate salts improved physicochemical properties giving rise to a more favourable dissolution profile with concomitant increase in systemic exposure relative to that observed following administration of the freebase.
This enhancement in exposure, following administration of the mesylate salt, therefore means that a higher exposure to the active ingredient is achieved giving rise to a greater efficacy and higher viral resistance barrier, both regarded as an essential feature for the treatment of viral infections. The enhancement of both efficacy and resistance barrier are judged to be prime features associated with the mesylate salt formulation Table 4: Comparison of exposures in the 13-week toxicity (free base) and the 26-week toxicity (mesylate salt) studies in rats after one administration. M male, F
female. Cmox is the maximal observed analyte concentration; AUC(0-24) is defined as the area under the analyte vs. time concentration up to 24 hours post dosing; calculated by linear up/In down summation
27 Free base Mesylate monohydrate Exposure ratio 13-week toxicity 26-week toxicity study 26-wts/13-wts.
study (13-wts) (26-wts) day 1 day 1 Dose [mg/kg/day] Gender Cmõ AUC (0-24) Cmax AUC(0_24) Cmax AU C(0-24) [ng/m1] [ngxh/ml] [ng/ml] [ngxh/ml]
M 13300 87900 16935 118752 1.3 1.4 248000 70324 633522 2.3 2.6 250 M 53900 567000 133776 1982721 2.5 3.5 10 F 15300 159000 17237 175125 1.1 1.1 50 F 35300 409000 77824 912978 2.2 2.2 250 F 68900 966000 146142 2473155 2.1 2.6 Table 5: Comparison of exposures in the 13-week toxicity (free base) and the 26-week 5 toxicity (mesylate monohydrate salt) studies in rats in week 13. M male, F female. Cmax is the maximal observed analyte concentration; AUC (0-24) is defined as the area under the analyte vs. time concentration up to 24 hours post dosing; calculated by linear up/In down summation Free base Mesylate monohydrate Exposure ratio 13-week toxicity 26-week toxicity study 26-wts/13-wts study (13-wts) (26-wts) week 13 week 13 Dose [mg/kg/day] Gender Cm" AUC(0-24) Cmax AUC(0.24) Cmax AUC(0-24) ing/m1] [ngxh/ml] [ng/ml] [ngxh/ml]
10 M 15000 133000 21840 227165 1.5 1.7 50 M 30000 332000 74719 959252 2.5 2.9 250 M 62800 661000 168968 2782092 2.7 4.2 10 F 25800 211000 25953 321135 1.0 1.5 50 F 40500 455000 106147 1205651 2.6 2.6 1172000 217283 3584983 2.6 3.1
study (13-wts) (26-wts) day 1 day 1 Dose [mg/kg/day] Gender Cmõ AUC (0-24) Cmax AUC(0_24) Cmax AU C(0-24) [ng/m1] [ngxh/ml] [ng/ml] [ngxh/ml]
M 13300 87900 16935 118752 1.3 1.4 248000 70324 633522 2.3 2.6 250 M 53900 567000 133776 1982721 2.5 3.5 10 F 15300 159000 17237 175125 1.1 1.1 50 F 35300 409000 77824 912978 2.2 2.2 250 F 68900 966000 146142 2473155 2.1 2.6 Table 5: Comparison of exposures in the 13-week toxicity (free base) and the 26-week 5 toxicity (mesylate monohydrate salt) studies in rats in week 13. M male, F female. Cmax is the maximal observed analyte concentration; AUC (0-24) is defined as the area under the analyte vs. time concentration up to 24 hours post dosing; calculated by linear up/In down summation Free base Mesylate monohydrate Exposure ratio 13-week toxicity 26-week toxicity study 26-wts/13-wts study (13-wts) (26-wts) week 13 week 13 Dose [mg/kg/day] Gender Cm" AUC(0-24) Cmax AUC(0.24) Cmax AUC(0-24) ing/m1] [ngxh/ml] [ng/ml] [ngxh/ml]
10 M 15000 133000 21840 227165 1.5 1.7 50 M 30000 332000 74719 959252 2.5 2.9 250 M 62800 661000 168968 2782092 2.7 4.2 10 F 25800 211000 25953 321135 1.0 1.5 50 F 40500 455000 106147 1205651 2.6 2.6 1172000 217283 3584983 2.6 3.1
28 Table 1A: the single-crystal structure parameters for N-[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate (batch BXR3NC1) formula C19H24N407S3 formula weight 516.62 Z, calculated density 2, 1.487 Mg - m-3.
F(000) 540 description and size of crystal colorless plate, 0.02 = 0.13 = 0.15 mm3 absorption coefficient 0.370 mm-1 min/max transmission 0.95/0.99 temperature 293K
radiation(wavelength) Mo Ka(A = 0.71073 A) Crystal system, space group triclinic, P -1 a 9.4908(7)A
9.5545(7) A
14.4137(9) A
a 86.130(3) 72.104(3) 68.253(4) V 1153.68(15)A3 min/max 8 2.426 / 30.065 number of collected reflections 43492 number of independent refections 6761 (merging r = 0.026) number of observed reflections 4955 (1>3.0a(I)) number of refined parameters 298 0.0313 (observed data with) rW 0.0432 (all data) goodness of fit 1.0736 residual electron density -0.28/0.33 e A3
F(000) 540 description and size of crystal colorless plate, 0.02 = 0.13 = 0.15 mm3 absorption coefficient 0.370 mm-1 min/max transmission 0.95/0.99 temperature 293K
radiation(wavelength) Mo Ka(A = 0.71073 A) Crystal system, space group triclinic, P -1 a 9.4908(7)A
9.5545(7) A
14.4137(9) A
a 86.130(3) 72.104(3) 68.253(4) V 1153.68(15)A3 min/max 8 2.426 / 30.065 number of collected reflections 43492 number of independent refections 6761 (merging r = 0.026) number of observed reflections 4955 (1>3.0a(I)) number of refined parameters 298 0.0313 (observed data with) rW 0.0432 (all data) goodness of fit 1.0736 residual electron density -0.28/0.33 e A3
29 Description of figures Figure 1 shows B) the X-ray powder diffraction spectrum of N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate (batch BXR3NC1) as calculated from single crystal data, and C) an overlay of the X-ray powder diffraction spectra of N-[5-(aminosulfonyI)-4-methyl-1,3-thiazol-2-y1]-N-methyl-244-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate of batch BXR3NC1 as measaured (blue line) and as calculated (red line).
D) Measured X-ray powder pattern of batch BXR3NC1 Figure 2 shows the X-ray structure of the N[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yly N-methyl-244-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate with indicated hydrogen bridges. It is shown that the nitrogen atom of the pyridinyl ring (right side bottom) is protonated and that a hydrogen bridge is formed between the hydrogen, which protonates the pyridinyi ring nitrogen, and one oxygen of the mesylate anion, and that another hydrogen bridge is formed between another oxygen of the mesylate anion and the hydrogen of the water molecule while the other hydrogen of the water molecule forms a hydrogen bridge with the oxygen of another mesylate anion.
Figure 3 shows the single-crystal X-ray structure analysis of the N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1J-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate as packing within the crystal. It is shown that the phenylpyridinyl ring systems are oriented in planes, which are parallel to each other.
D) Measured X-ray powder pattern of batch BXR3NC1 Figure 2 shows the X-ray structure of the N[5-(aminosulfony1)-4-methyl-1,3-thiazol-2-yly N-methyl-244-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate with indicated hydrogen bridges. It is shown that the nitrogen atom of the pyridinyl ring (right side bottom) is protonated and that a hydrogen bridge is formed between the hydrogen, which protonates the pyridinyi ring nitrogen, and one oxygen of the mesylate anion, and that another hydrogen bridge is formed between another oxygen of the mesylate anion and the hydrogen of the water molecule while the other hydrogen of the water molecule forms a hydrogen bridge with the oxygen of another mesylate anion.
Figure 3 shows the single-crystal X-ray structure analysis of the N45-(aminosulfony1)-4-methyl-1,3-thiazol-2-y1J-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate as packing within the crystal. It is shown that the phenylpyridinyl ring systems are oriented in planes, which are parallel to each other.
Claims (8)
1. Method for synthesizing N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-methyl-2-[4-(2-pyridinyl)phenyl]acetamide according to the following steps:
Step A:
Reacting compound A of the following general formula A*
wherein R1 represents a leaving group and R2 represents an alkyl residue with 1 to 6 carbon atoms or a cycloalkyl residue with 3 to 6 carbon atoms with a boronic acid derivative, borolane, borinane or diboronic acid reagent under elimination of R1-H or R1-B(OR)2 and formation of an intermediate boronic acid derivative of compound A, wherein the intermediate boronic acid derivative is then reacted with the pyridine compound B of the following general formula B*
wherein R3 represents a leaving group under basic conditions in order to directly obtain (4-pyridin-2-ylphenyl)acetic acid which is then purified, Step B:
Reacting (4-pyridin-2-ylphenyl)acetic acid obtained from step A with 4-methyl-(methylamino)-1,3-thiazole-5-sulfonamide in order to obtain N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide of the formula
Step A:
Reacting compound A of the following general formula A*
wherein R1 represents a leaving group and R2 represents an alkyl residue with 1 to 6 carbon atoms or a cycloalkyl residue with 3 to 6 carbon atoms with a boronic acid derivative, borolane, borinane or diboronic acid reagent under elimination of R1-H or R1-B(OR)2 and formation of an intermediate boronic acid derivative of compound A, wherein the intermediate boronic acid derivative is then reacted with the pyridine compound B of the following general formula B*
wherein R3 represents a leaving group under basic conditions in order to directly obtain (4-pyridin-2-ylphenyl)acetic acid which is then purified, Step B:
Reacting (4-pyridin-2-ylphenyl)acetic acid obtained from step A with 4-methyl-(methylamino)-1,3-thiazole-5-sulfonamide in order to obtain N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide of the formula
2. Method according to claim 1 further comprising step C:
Converting N-[5-(aminosulfonyl)-4-methyl-1 ,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide with methanesulfonic acid in a mixture of an organic solvent and water to crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate of the formula
Converting N-[5-(aminosulfonyl)-4-methyl-1 ,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide with methanesulfonic acid in a mixture of an organic solvent and water to crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide methanesulfonic acid monohydrate of the formula
3. Method according to claim 1, wherein R1 and R3 are independently of each other selected form ¨F, ¨Cl, ¨Br, ¨I, ¨OMs, ¨OTf and ¨OTs.
4. Method according to claim 1, wherein the boronic acid derivative, borolane, borinane or diboronic acid reagent is selected from:
wherein R', R", R a, R b, R c, R d, R e and R f represent independently of each other a substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms.
wherein R', R", R a, R b, R c, R d, R e and R f represent independently of each other a substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms.
5. Method according to claim 1, wherein for the preparation of the intermediate boronic acid derivative or borolane reagent, the reagents palladium acetate, triethylamine and triphenylphosphine or PdCl2(PPh3)2 and triethylamine are used.
6. Method according to claim 1, wherein Step 13 is carried out with EDC x HCl as coupling agent in a THF / NMP solvent mixture.
7. Method according to claim 2, wherein the mixture of of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in an organic solvent and water yields a supersaturated solution upon addition of methanesulfonic acid at elevated temperatures from which the N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide methanesulfonic acid monohydrate crystallizes after either extended stirring, seeding or cooling.
8. Method according to any one of claims 2 or 7 further comprising step D:
Preparing a pharmaceutical composition of the crystalline N-[5-(aminosulfonyl)-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide methanesulfonic acid monohydrate with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
Preparing a pharmaceutical composition of the crystalline N-[5-(aminosulfonyl)-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide methanesulfonic acid monohydrate with at least one pharmaceutically acceptable carrier, excipient, solvent and/or diluent.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11007803.7 | 2011-09-26 | ||
EP11007803A EP2573085A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
EP11007823A EP2573086A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
EP11007823.5 | 2011-09-26 | ||
CA2791142A CA2791142C (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2791142A Division CA2791142C (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2939529A1 CA2939529A1 (en) | 2013-03-26 |
CA2939529C true CA2939529C (en) | 2018-07-03 |
Family
ID=56855901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2939529A Active CA2939529C (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2939529C (en) |
-
2012
- 2012-09-26 CA CA2939529A patent/CA2939529C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2939529A1 (en) | 2013-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9340535B2 (en) | N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
AU2012314473B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. | |
CA2939529C (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
EP2598502B1 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. | |
NZ621615B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
NZ718867B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20161121 |